Challenges in RNA Processing and Analysis from Liquid Biopsies
Explore other webinars
Challenges in RNA Processing and Analysis from Liquid Biopsies
45 minutes + live Q&A
Featured Speakers
Key Questions We Will Answer
- What is the best method of sample preparation to maintain RNA integrity for liquid biopsy
- What is the expected yield of RNA from various liquid biopsy samples?
- What is the best method of quantification for ultra-low RNA concentrations?
- How can I maximize RNA concentration for downstream applications, such as NGS?
- What is the difference between RNA-seq and small RNA-seq, and which one should I use with my liquid biopsy samples?
Abstract
Join our expert panel of scientists in this Live Q&A session to explore all of the complexities of processing and analyzing RNA from liquid biopsy samples. Liquid biopsy samples are increasingly becoming one of the most valuable, minimally-invasive sources of information as the basis of diagnosis and disease monitoring as well as disease prevention. Biospecimens such as plasma, serum and urine contain various biomarkers that provide key insights into changes within the genome, epigenome, transcriptome and proteome of a patient. In this webinar, we'll answer all of your RNA questions related to biological specimen handling, RNA purification, quantification and downstream applications, including qRT-PCR and Next Generation Sequencing.
About the Speakers
1) Dr. Moemen Abdalla, PhD
Dr. Moemen Abdalla, MSc, PhD is the Director of Marketing and Sales at Norgen Biotek Corp. and has taken on the role of Laboratory Lead for Norgen’s COVID-19 testing service. Succeeding his masters in Biochemistry at Alexandria University, Egypt, Dr. Abdalla completed his PhD at Brock University, where he specialised in liver cancer biomarker discovery from urine. Dr. Abdalla joined the team at Norgen Biotek over 12 years ago, specializing in sample preparation and molecular diagnostics. During his time at Norgen, Dr. Abdalla has developed many cutting- edge research and diagnostic tools for scientific use. As the Director of Marketing and Sales, he and his team strategically employed global awareness initiatives that would position Norgen as a thought leader within the industry. He leveraged Norgen’s outstanding technology, developed in-house, to laboratories and ensured a quality product was always distributed to the labs in need. With his team of research scientists, they ensured the efficacy of Norgen’s testing service.
2) Dr. Patricia Barbalho, PhD
Dr. Patricia Barbalho is the most recent addition to Norgen’s ever growing Research & Development Team. With a PhD in medical genetics, she currently works as a Research Scientist overseeing of the testing and validation of Norgen’s product portfolio including nucleic acid purification kits, MDx assays as well biospecimen collection devices for regulatory submission for in vitro diagnostics. Dr. Barbalho plays an instrumental role in achieving regulatory certifications from international bodies for Norgen’s product line including CE marking, Health Canada and the FDA.
3) Dr. Alex Chauhan, PhD
Dr. Alex Chauhan, PhD, is an NGS Scientist on Norgen’s Next Generation Sequencing Services Team. With a PhD in applied sciences and cancer biology, Dr. Chauhan has extensive expertise working with liquid biopsy samples of all types. He oversees all client NGS projects, and specifically works with Small RNA-Sequencing for challenging ultra-low input sample types, such as cerebral spinal fluid and plasma/serum. In addition to his contributions to the NGS team, Dr. Chauhan holds a valuable role in Research and Development for Norgen’s line of cell-free RNA and cell-free DNA purification kits.